These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 8794983)

  • 21. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
    Hönigsmann H; Jaschke E; Gschnait F; Brenner W; Fritsch P; Wolff K
    Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M; Ros AM
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAMAM dendrimers as solubilizers and hosts for 8-methoxypsoralene enabling transdermal diffusion of the guest.
    Borowska K; Laskowska B; Magoń A; Mysliwiec B; Pyda M; Wołowiec S
    Int J Pharm; 2010 Oct; 398(1-2):185-9. PubMed ID: 20655371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model analysis of flux enhancement across hairless mouse skin induced by chemical permeation enhancers.
    He N; Warner KS; Higuchi WI; Li SK
    Int J Pharm; 2005 Jun; 297(1-2):9-21. PubMed ID: 15907593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
    Shephard SE; Panizzon RG
    Dermatology; 1999; 199(2):106-12. PubMed ID: 10559574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinetic in patients' serum.
    Saïd A; Makki S; Muret P; Toubin G; Humbert P; Millet J
    Exp Dermatol; 1997 Apr; 6(2):57-63. PubMed ID: 9209885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro percutaneous absorption of arildone, a highly lipophilic drug, and the apparent no-effect of the penetration enhancer Azone in excised human skin.
    Baker EJ; Hadgraft J
    Pharm Res; 1995 Jul; 12(7):993-7. PubMed ID: 7494819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal delivery of antiparkinsonian agent, benztropine. I. Effect of vehicles on skin permeation.
    Gorukanti SR; Li L; Kim KH
    Int J Pharm; 1999 Dec; 192(2):159-72. PubMed ID: 10567747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microemulsions for topical delivery of 8-methoxsalen.
    Baroli B; López-Quintela MA; Delgado-Charro MB; Fadda AM; Blanco-Méndez J
    J Control Release; 2000 Oct; 69(1):209-18. PubMed ID: 11018558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma and skin concentration of 5-methoxypsoralen in psoriatic patients after oral administration.
    Zucchi A; Raho E; Marconi B; Nicoli S; Santini M; Allegra F; Colombo P; Bettini R; Santi P
    J Invest Dermatol; 2001 Aug; 117(2):379-82. PubMed ID: 11511320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA in psoriatic epidermis.
    Sondergaard J; Lerche A; Bohr V; Leik V; Wadskov S
    Acta Derm Venereol Suppl (Stockh); 1979; 87():59-63. PubMed ID: 294785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
    Shephard SE; Nestle FO; Panizzon R
    Photodermatol Photoimmunol Photomed; 1999 Apr; 15(2):64-74. PubMed ID: 10321518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of 8-methoxypsoralen following PUVA-bath photochemotherapy.
    von Kobyletzki G; Hoffmann K; Kerscher M; Altmeyer P
    Photodermatol Photoimmunol Photomed; 1998; 14(3-4):136-8. PubMed ID: 9779504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
    Nimkulrat P; Leenutaphong V; Sudtim S
    J Med Assoc Thai; 2005 Oct; 88(10):1406-11. PubMed ID: 16519387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A; Ortel B; Rappersberger K; Hönigsmann H
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized double-blind comparative study of 8-methoxypsoralen bath plus UV-A treatment regimens.
    Berroeta L; Man I; Dawe RS; Ferguson J; Ibbotson SH
    Actas Dermosifiliogr; 2010 Oct; 101(8):729-30. PubMed ID: 20965019
    [No Abstract]   [Full Text] [Related]  

  • 37. Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
    Studer-Sachsenberg EM; Piletta PA; Fathi M; Saurat JH; Salomon D
    Dermatology; 1997; 195(1):81-3. PubMed ID: 9267751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of psoriasis with polyethylene sheet bath PUVA.
    Streit V; Wiedow O; Christophers E
    J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):208-10. PubMed ID: 8708022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of the effect of lipophilicity on the in vitro permeability and tissue reservoir characteristics of topically applied solutes in human skin layers.
    Cross SE; Magnusson BM; Winckle G; Anissimov Y; Roberts MS
    J Invest Dermatol; 2003 May; 120(5):759-64. PubMed ID: 12713577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.